Last: | $ |
---|---|
Change Percent: | -0.50% |
Open: | $18.20 |
Close: | $18.04 |
High: | $18.77 |
Low: | $17.605 |
Volume: | 215,638 |
Last Trade Date Time: | 02/12/2020 04:43:42 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $18.20 | $18.04 | $18.77 | $17.605 | 215,638 | 02-12-2020 |
$ | $18.09 | $18.13 | $19.97 | $17.69 | 30,889 | 02-11-2020 |
$ | $19.66 | $18.15 | $19.66 | $18.03 | 19,529 | 02-10-2020 |
$ | $19.97 | $19.77 | $20.15 | $19.09 | 61,542 | 02-07-2020 |
$ | $20.45 | $19.99 | $21.29 | $19.00 | 43,078 | 02-06-2020 |
$ | $20.45 | $20.71 | $21.53 | $19.80 | 50,094 | 02-05-2020 |
$ | $21.08 | $20.43 | $21.51 | $20.26 | 38,224 | 02-04-2020 |
$ | $20.81 | $21.04 | $21.48 | $20.485 | 48,747 | 02-03-2020 |
$ | $22.49 | $20.65 | $22.49 | $20.07 | 77,271 | 01-31-2020 |
$ | $22.64 | $22.50 | $23.48 | $21.46 | 109,649 | 01-30-2020 |
$ | $22.98 | $23.50 | $24.50 | $22.01 | 128,349 | 01-29-2020 |
$ | $24.07 | $22.955 | $24.40 | $22.5339 | 27,372 | 01-28-2020 |
$ | $21.69 | $23.82 | $24.98 | $20.105 | 104,890 | 01-27-2020 |
$ | $20.9543 | $22.10 | $22.18 | $20.83 | 88,730 | 01-24-2020 |
$ | $22.84 | $21.10 | $22.85 | $20.93 | 48,165 | 01-23-2020 |
$ | $22.83 | $22.59 | $23.20 | $22.09 | 52,884 | 01-22-2020 |
$ | $23.30 | $22.96 | $24.35 | $22.27 | 80,542 | 01-21-2020 |
$ | $24.43 | $23.50 | $24.47 | $22.64 | 93,889 | 01-20-2020 |
$ | $24.43 | $23.50 | $24.47 | $22.64 | 93,888 | 01-17-2020 |
$ | $24.34 | $24.19 | $24.62 | $23.70 | 248,224 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Exagen Inc. Company Name:
XGN Stock Symbol:
NYSE Market:
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announc...
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a d...
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Record total revenue of $52...